Skip to main content

Table 2 Linear mixed models of General Physical Symptoms, Treatment Side Effects, and Acute Distress

From: Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

 General Physical SymptomsaTreatment Side EffectsbAcute Distressc
EffectEstimate (SE)P-valueEstimate (SE)P-valueEstimate (SE)P-value
Intercept58.50 (8.141)< 0.000159.60 (5.877)< 0.000160.10 (9.236)< 0.0001
Time (months) since diagnosis− 0.10 (0.040)0.018− 0.12 (0.024)< 0.0001− 0.17 (0.039)< 0.0001
Treatment: cetuximab±RT (vs. cisplatin±RT)1.19 (1.667)0.475−0.32 (1.221)0.7925.77 (2.013)0.004
Treatment* time since diagnosis0.13 (0.14)0.3520.05 (0.084)0.540−0.18 (0.143)0.205
Age at diagnosis−0.25 (0.070)0.001−0.14 (0.051)0.005−0.27 (0.076)0.001
Male (vs. female)−2.42 (1.342)0.072−2.13 (0.974)0.029−6.88 (1.487)< 0.0001
White (vs. minority/unknown)0.41 (1.212)0.733−0.41 (0.883)0.6443.74 (1.347)0.006
Impaired composite performance status (vs. not impaired)1.94 (2.438)0.4272.01 (1.755)0.252−0.13 (2.700)0.962
Weighted index of comorbid conditions0.67 (0.641)0.2980.57 (0.465)0.2201.67 (0.714)0.020
Smoking status: current or past (vs. never/unknown/undocumented)2.64 (1.523)0.0830.40 (1.102)0.7153.98 (1.687)0.019
Alcohol status0.5340.1760.055
 Current or past abuse (vs. never/unknown/undocumented)0.89 (1.591)0.5761.05 (1.153)0.3632.09 (1.761)0.235
 Current or past use (vs. never/unknown/undocumented)−0.66 (1.302)0.614−0.82 (0.944)0.386−1.61 (1.44)0.262
Stage at start: Stage III (vs. Stage IV)0.11 (1.156)0.922−0.15 (0.836)0.854−0.05 (1.273)0.971
Oral (vs. non-oral)−1.64 (3.064)0.5920.26 (2.249)0.908−3.48 (3.491)0.319
Pharynx (vs. non-pharynx)−0.04 (2.987)0.9891.88 (2.193)0.393−0.18 (3.406)0.959
Larynx (vs. non-larynx)−0.73 (3.144)0.8170.00 (2.314)0.999−2.86 (3.581)0.425
HPV test results (positive vs. non-positive)2.60 (3.273)0.4283.11 (2.354)0.187−5.02 (3.686)0.174
P16 test results (positive vs. non-positive)1.469 (1.350)0.2770.95 (0.977)0.3323.17 (1.479)0.033
Feeding tube placement (vs. not placed)1.066 (1.158)0.3560.866 (0.841)0.3041.26 (1.282)0.327
BMI−0.05 (0.093)0.5810.005 (0.067)0.942−0.06 (0.103)0.540
Insurance0.0100.0520.047
 Only public (vs. only private)4.85 (1.555)0.0022.67 (1.128)0.0184.50 (1.728)0.010
 Both public and private (vs. only private)3.54 (1.458)0.0151.70 (1.059)0.1092.98 (1.617)0.066
 Other/unknown/undocumented (vs. only private)4.395 (3.468)0.2054.43 (2.574)0.0865.09 (3.958)0.199
US region South (vs. non-South)4.12 (5.476)0.4521.167 (3.942)0.7673.68 (6.336)0.561
  1. Reference level for each comparison is in parentheses
  2. BMI body mass index, HPV human papilloma virus, RT radiation therapy, SE standard error, US United States
  3. aAnalysis is based on 237 patients and 1859 observations
  4. bAnalysis is based on 237 patients and 1866 observations
  5. cAnalysis is based on 237 patients and 1596 observations
  6. *refers to an interaction